Home > Dermatology > EADV 2022 > Kappa-opioid receptor agonist shows remarkable efficacy in notalgia paresthetica

Kappa-opioid receptor agonist shows remarkable efficacy in notalgia paresthetica

Presented By
Prof. Mark Lebwohl, Icahn School of Medicine at Mount Sinai, NY, USA
Conference
EADV 2022
Trial
Phase 2, KOMFORT
According to the results of a phase 2 trial, difelikefalin leads to rapid decrease in pruritus in patients with notalgia paresthetica, a very common, underdiagnosed condition with a high medical need due to the lack of treatment possibilities. Significant changes from placebo in pruritus were already seen on day 1. In the phase 2 KOMFORT trial (NCT04706975), the kappa-opioid receptor agonist difelikefalin in an oral preparation was evaluated for the treatment of moderate-to-severe pruritus in patients with a confirmed diagnosis of notalgia paresthetica, a common sensory neuropathy of the back characterised by chronic pruritus. After a run-in-period, participants were treated with difelikefalin (2 mg, twice daily) or placebo for 8 weeks. The primary study endpoint was the change from baseline in the weekly mean change of daily ≥4-point i...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on